Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Leukemia·2026
Same author

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.

British journal of haematology·2026
Same author

SIGN of the times: DC-SIGN and the follicular lymphoma niche.

Blood·2026
Same author

Same-Slide Spatial Multi-Omics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.

Cancer discovery·2026
Same author

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Blood·2026
Same author

A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures.

Nature communications·2026
Same journal

Author response to Zhang and Chen.

British journal of haematology·2026
Same journal

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

British journal of haematology·2026
Same journal

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026
Same journal

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026
Same journal

Novel germline GATA1s-generating variant associates with somatic STAG2 variants in hypoplastic myelodysplastic neoplasm.

British journal of haematology·2026
Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2025

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.2K

Epstein-Barr virus-associated lymphomas decoded.

Karolina Bednarska1, Rakin Chowdhury2,3, Joshua W D Tobin1,3

  • 1Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia.

British Journal of Haematology
|December 29, 2023
PubMed
Summary
This summary is machine-generated.

Epstein-Barr virus (EBV) plays a key role in various lymphomas. Recent advances offer new targeted therapies and monitoring strategies for EBV-associated cancers.

Keywords:
EBVEBV latencyEBV-associated lymphomaEBV-specific T cellsHodgkin lymphomaPTLD

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

3.9K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.4K

Related Experiment Videos

Last Updated: Jul 6, 2025

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.2K
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

3.9K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.4K

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Epstein-Barr virus (EBV) is implicated in diverse B- and T-cell lymphomas.
  • The precise role of EBV in B-cell cancer development and the tumor microenvironment remains unclear.
  • Recent classifications highlight EBV's distinct features in lymphoproliferative disorders.

Purpose of the Study:

  • To review recent advancements in understanding EBV-associated lymphomas.
  • To explore novel therapeutic strategies targeting EBV and host immune responses.
  • To discuss the utility of EBV in monitoring treatment efficacy.

Main Methods:

  • Review of current literature and classification systems (ICC, WHO-HAEM5).
  • Analysis of biological insights into EBV pathogenesis.
  • Examination of therapeutic approaches and disease monitoring techniques.

Main Results:

  • Significant progress in understanding EBV's biological mechanisms in lymphomagenesis.
  • Development of targeted therapies leveraging EBV and immune responses.
  • Emerging methods for using EBV to track treatment outcomes.

Conclusions:

  • New insights into EBV-associated lymphomas are driving innovative therapeutic strategies.
  • Harnessing EBV and immune responses shows promise for targeted cancer treatment.
  • EBV monitoring offers a valuable tool for assessing therapeutic response in lymphomas.